First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.

Jiaqi HanNi ZengKun TianZijian LiuLongjiang SheZhu WangJinlan HeNianyong Chen

Published in: Head & neck (2023)

From the Chinese payers' perspective, first-line immunotherapy combination therapies provided significant survival and cost-effectiveness superiority over chemotherapy alone for patients with R/M-NPC at the WTP of $38 029/QALY. Among the three chemo-immunotherapy groups, TOGP was the most cost-effective option.

Keyphrases

systematic review
squamous cell carcinoma
locally advanced
small cell lung cancer
photodynamic therapy
meta analyses
radiation therapy
cancer therapy